Document Detail


Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
MedLine Citation:
PMID:  10609798     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated beta2-microglobulin (13/20 had >4 microg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4%, 17/23 patients had BMLI > or = 1%). Of the 24 patients, 19 (79%) died of disease progression and 5 (21%) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.
Authors:
R Fonseca; J D Hoyer; P Aguayo; S M Jalal; G J Ahmann; S V Rajkumar; T E Witzig; M Q Lacy; A Dispenzieri; M A Gertz; R A Kyle; P R Greipp
Related Documents :
2178458 - Acute megakaryoblastic leukemia in children identified by immunological marker studies.
2004308 - Extramedullary blast crisis in a patient with philadelphia chromosome-positive chronic ...
12506758 - Prognostic value of tumour cell detection in peripheral blood of breast cancer patients.
2931098 - Lineage specific classification of leukaemia: results of the analysis of sixty cases of...
6611388 - Predictive value of perfusion defect size using n-isopropyl-(i-123)-p-iodoamphetamine e...
3292788 - Glucose-6-phosphate dehydrogenase deficiency in thailand: the influence on the clinical...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  35     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1999 Nov 
Date Detail:
Created Date:  2000-02-14     Completed Date:  2000-02-14     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  599-605     Citation Subset:  IM    
Affiliation:
Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Blood Cell Count
Calcium / blood
Chromosomes, Human, Pair 11 / genetics,  ultrastructure*
Chromosomes, Human, Pair 14 / genetics,  ultrastructure*
Creatinine / blood
Disease Progression
Follow-Up Studies
Hemoglobins / analysis
Humans
Leukemia, Plasma Cell / genetics,  mortality,  pathology
Multiple Myeloma / drug therapy,  genetics*,  mortality,  pathology
Neoplastic Cells, Circulating
Prognosis
Survival Analysis
Translocation, Genetic*
Tumor Markers, Biological / analysis
beta 2-Microglobulin / analysis
Grant Support
ID/Acronym/Agency:
CA 62242/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Hemoglobins; 0/Tumor Markers, Biological; 0/beta 2-Microglobulin; 60-27-5/Creatinine; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
Next Document:  Improvement of quality of life after splenectomy in an HTLV-I carrier with T-cell prolymphocytic leu...